MET and liver cancer: Some researchers have shown that miR-26a could inhibit the activity of angiogenesis in liver cancer, acute myocardial infarction, and diabetes by directly targeting signaling pathways, such as hepatocyte growth factor-cMet pathway and BMP/Smad1 pathway [27, 28, 38].